Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07VMC
|
||||
| Former ID |
DIB007525
|
||||
| Drug Name |
LY-243062
|
||||
| Indication | Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25] | Terminated | [1] | ||
| Company |
Eli Lilly & Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
n1(cc2c3c1cccc3[C@@H]1[C@H](N(C[C@@H](C1)CSC)CCC)C2)C(C<br />)C
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005079) | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005079) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.